Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLifecore Biomedical Inc.

Lifecore Biomedical Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
6.4 USD 0.03 ( 0.47%)
Last update at 2026-11-11T21:00:00Z
VOLUME
149717
Market Cap
170.45M

Momentum Score

…

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.37
Low
6.40
High
52 Week Price Range
4.50
Low
11.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lifecore Biomedical makes hyaluronic acid-based medical products and provides contract development and manufacturing services for sterile injectables and viscoelastic solutions used in ophthalmology, orthopedics and aesthetics. Long-term growth may be supported by rising demand for biopharma CDMO capacity, aging-population-driven ophthalmic procedures and expansion of aesthetic treatments. Investors may find the company attractive for its specialized HA expertise and diversified revenue between proprietary products and manufacturing services.

Material risks include regulatory and manufacturing execution exposure, competitive pressures in CDMO and aesthetics, and customer concentration that could cause revenue volatility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.37
Dividend Yield
-
Revenue TTM
103.27M
Revenue Per Share
3.45
Gross Profit TTM
27.29M
Debt / Equity
1.42
ROE
-104.52%
Net Debt
151.45M
ROCE
1.60%
Diluted EPS TTM
-2.12

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Income before tax -51.92M -52.12M -40.47M -51.31M 3.64M
Minority interest - - - 0.00M 0.00M
Net income -46.08M -97.43M -32.66M -38.19M 2.12M
Selling general administrative 43.02M 46.13M 65.36M 72.19M 64.06M
Gross profit 50.55M 50.37M 81.47M 74.99M 81.00M
Reconciled depreciation 13.51M 17.88M 19.87M 18.84M 15.23M
Ebit 3.46M -85.91M -6.86M -8.30M -8.01M
Ebitda 21.25M -68.03M 13.00M -12.59M 7.22M
Depreciation and amortization 17.79M 17.88M 19.87M -4.29M 15.23M
Operating income 3.46M -3.60M -6.86M -8.30M -8.01M
Other operating expenses 185.71M 189.38M 538.27M 598.66M 552.08M
Interest expense 17.26M 17.36M 15.34M 9.60M 5.23M
Tax provision 0.30M -5.84M -7.80M -13.12M 1.52M
Interest income 0.07M 0.08M 0.05M 0.10M 0.14M
Net interest income -18.12M -17.28M -15.30M -9.50M -5.08M
Income tax expense -5.84M -5.84M -7.80M -13.12M 1.52M
Total revenue 185.79M 185.79M 544.16M 590.37M 557.56M
Total operating expenses 50.47M 53.97M 75.59M 83.29M 75.53M
Cost of revenue 135.23M 135.42M 462.69M 515.38M 476.56M
Total other income expense net -55.38M -48.52M -33.60M -43.01M 11.65M
Discontinued operations -33.19M -51.16M -23.10M -16.32M -1.71M
Net income from continuing ops -69.00M -46.28M -32.66M -38.19M 2.12M
Net income applicable to common shares -102.19M -97.43M -32.66M -38.19M 0.41M
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Total assets 295.44M 295.16M 502.92M 541.31M 519.09M
Intangible assets 15.55M 15.55M 36.12M 38.10M 45.25M
Other current assets 7.05M 7.05M 7.35M 14.23M 8.26M
Total liab 187.30M 187.22M 300.14M 310.27M 248.95M
Total stockholder equity 108.14M 107.94M 202.78M 231.04M 270.14M
Other current liab 17.06M 16.89M 20.30M 19.01M 20.83M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -58.66M -58.85M 38.58M 71.25M 109.71M
Other liab 3.49M 0.42M 11.26M 14.56M 20.65M
Good will 13.88M 13.88M 69.39M 69.39M 76.74M
Other assets 3.21M 3.00M 157.67M 2.16M 2.29M
Cash 1.64M 1.64M 1.29M 0.36M 1.08M
Total current liabilities 79.41M 79.23M 101.89M 164.39M 137.09M
Current deferred revenue 0.92M 0.92M 1.13M 0.35M 0.50M
Net debt 151.45M 151.54M 220.11M 220.76M 151.44M
Short term debt 45.62M 45.62M 32.89M 93.38M 61.79M
Short long term debt 0.49M 40.60M 29.00M 88.95M 61.79M
Short long term debt total 153.09M 153.19M 221.40M 221.12M 152.52M
Other stockholder equity 167.35M 167.35M 165.53M 162.58M 160.34M
Property plant equipment 134.59M 139.01M 137.38M 217.66M 200.03M
Total current assets 123.99M 123.71M 148.32M 157.11M 133.04M
Long term investments - - 45.10M 56.90M 61.10M
Net tangible assets -19.92M 78.51M 143.24M 123.55M 148.16M
Net receivables 48.33M 48.17M 70.01M 76.21M 69.56M
Long term debt 101.27M 97.58M 164.90M 101.36M 87.19M
Inventory 66.97M 66.84M 69.66M 66.31M 54.13M
Accounts payable 15.80M 15.80M 47.57M 51.65M 53.97M
Accumulated other comprehensive income -0.59M -0.59M -1.36M -2.81M 0.06M
Non currrent assets other 3.00M 3.00M 3.61M 2.16M 2.93M
Non current assets total 171.45M 171.45M 354.60M 384.21M 386.05M
Capital lease obligations 10.98M 15.01M 27.50M 30.80M 3.53M
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Investments -4.15M 45.10M 45.10M 45.10M 7.00M
Change to liabilities 19.22M 9.32M -5.20M -1.40M 16.74M
Total cashflows from investing activities -4.15M 81.77M -10.86M -23.89M -96.80M
Net borrowings 19.40M -55.41M 7.47M 41.77M 79.91M
Total cash from financing activities -57.02M -57.02M -3.42M 40.02M 79.03M
Change to operating activities 4.48M -3.83M 11.67M -7.45M 1.87M
Net income -97.24M -97.43M -32.66M -38.19M 0.41M
Change in cash 0.35M 0.35M 0.74M -0.91M -1.75M
Begin period cash flow 1.29M 1.29M 0.55M 1.47M 3.22M
End period cash flow 1.64M 1.64M 1.29M 0.55M 1.47M
Total cash from operating activities -24.40M -24.40M 15.02M -17.04M 16.02M
Issuance of capital stock 42.90M 0.00M 0.00M 0.03M 0.33M
Depreciation 17.79M 17.88M 19.87M 18.84M 15.23M
Other cashflows from investing activities 13.47M -9.84M -9.84M 0.36M 0.55M
Change to inventory -6.08M -5.96M -3.35M -12.18M -10.93M
Change to account receivables -6.29M -6.14M 5.78M -6.64M -8.86M
Other cashflows from financing activities 73.50M 73.50M 259.11M 145.01M 117.79M
Change to netincome 32.15M 61.75M 18.93M 29.69M 1.98M
Capital expenditures 28.13M 28.13M 23.77M 26.69M 44.73M
Change in working capital -6.70M -6.60M 8.89M -27.66M -1.18M
Stock based compensation 2.61M 2.61M 3.36M 2.42M 3.56M
Other non cash items 66.03M 66.03M 23.46M 32.99M -2.91M
Free cash flow -52.53M -52.53M -8.75M -43.73M -28.71M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LFCR
Lifecore Biomedical Inc.		 0.03
0.47%		 6.40 - 10.45 1.79 1.57 2.70 -8.45
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Lifecore Biomedical Inc.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

3515 Lyman Boulevard, Chaska, MN, United States, 55318

952 368 4300

https://www.lifecore.com

459

Name Title Year Born
Mr. James G. Hall CEO, Pres & Director 1963
Mr. John D. Morberg CFO & Sec. 1964
Dr. Albert D. Bolles Ph.D. Pres of Curation Foods, Inc. 1958
Mr. Aaron Perlitsh Director of Internal Audit & Chief Compliance Officer NA
Mr. Parker K. Javid VP 1969
Dr. Kipling Thacker Ph.D. VP & Chief Scientist 1955
Mr. James G. Hall CEO, President & Director 1963
Mr. John D. Morberg Executive VP & CFO 1964
Dr. Albert D. Bolles Ph.D. President of Curation Foods, Inc. 1958
Mr. Steve W. Laninga Vice President of Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -2.89%

  • Communication Services

    +0.25%

  • Consumer Cyclical

    +0.37%

  • Consumer Defensive

    -0.02%

  • Energy

    -0.30%

  • Financial Services

    -1.06%

  • Healthcare

    -0.73%

  • Industrials

    -0.49%

  • Real Estate

    +0.22%

  • Technology

    -1.52%

  • Utilities

    +0.08%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…